Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

5/1/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TNGX alert in real time by email

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:

Elizabeth Hickin

[email protected]

[email protected]

Get the next $TNGX alert in real time by email

Date	Price Target	Rating	Analyst
7/17/2024	$19.00	Buy	Jefferies
4/4/2024		Overweight	Cantor Fitzgerald
2/12/2024	$18.00	Overweight	Piper Sandler
12/8/2023	$16.00	Buy	B. Riley Securities
10/20/2022	$10.00	Neutral → Buy	H.C. Wainwright
9/20/2021	$25.00	Outperform	SVB Leerink
9/7/2021	$12.00	Outperform	Wedbush
9/7/2021	$20.00	Outperform	Wedbush

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Chat with this insight

Recent Analyst Ratings for
$TNGX

$TNGX
Press Releases

Fastest customizable press release news feed in the world

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

$TNGX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Peters Malte was granted 6,250 shares, increasing direct ownership by 56% to 17,500 units (SEC Form 4)

Director Calhoun Lesley Ann was granted 6,250 shares, increasing direct ownership by 100% to 12,500 units (SEC Form 4)

Director Rothenberg Mace was granted 6,250 shares, increasing direct ownership by 20% to 37,500 units (SEC Form 4)

$TNGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Tango Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Tango Therapeutics

Piper Sandler initiated coverage on Tango Therapeutics with a new price target

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Chat with this insight

Recent Analyst Ratings for $TNGX

$TNGX Press Releases

Fastest customizable press release news feed in the world

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

$TNGX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Peters Malte was granted 6,250 shares, increasing direct ownership by 56% to 17,500 units (SEC Form 4)

Director Calhoun Lesley Ann was granted 6,250 shares, increasing direct ownership by 100% to 12,500 units (SEC Form 4)

Director Rothenberg Mace was granted 6,250 shares, increasing direct ownership by 20% to 37,500 units (SEC Form 4)

$TNGX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Tango Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Tango Therapeutics

Piper Sandler initiated coverage on Tango Therapeutics with a new price target

Recent Analyst Ratings for
$TNGX

$TNGX
Press Releases

$TNGX
Insider Trading

$TNGX
Analyst Ratings